LIV-1-positive metastatic breast cancer

15:48 EST 24th November 2017 | BioPortfolio

Antibody-drug conjugates (ADCs) utilize the targeting ability of antibodies to deliver cytotoxic agents directly to cancer cells. Seattle Genetics is developing SGn‑lIV1a, an ADC consisting of an anti-LIV-1 (SLC39A6) monoclonal antibody linked to the synthetic cytotoxic agent monomethyl auristatin E, for the potential treatment of metastatic breast cancer.

Breast cancer is the second most common cancer in women worldwide, accounting for 16 percent of all female cancer, and is estimated to cause 500,000 deaths per year. The LIV-1 protein has been demonstrated by Seattle to be expressed in 92 percent of breast tumors analyzed, with limited expression in normal tissues.

The company initiated a phase I trial of SGNLIV1A in the U.S. in October 2013 to assess safety and antitumor activity in up to 70 LIV-1-positive metastatic breast cancer patients. The targeted approach is expected to enhance anticancer activity whilst reducing the toxic side effects of traditional chemotherapy. 

Adapted from - Thomson Reuters Cortellis Competitive Intelligence

Quick Search

review and buy LIV-1-positive metastatic breast cancer market research data and corporate reports here